- Home
- VRTX
as 11-18-2024 4:00pm EST
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 128.5B | IPO Year: | 1991 |
| Target Price: | $513.58 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 29 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $346.29 - $519.88 | Next Earning Date: | 11-04-2024 |
| Revenue: | $10,625,800,000 | Revenue Growth: | 10.06% |
| Revenue Growth (this year): | 12.2% | Revenue Growth (next year): | 8.31% |
Stock Insider Trading Activity of Vertex Pharmaceuticals Incorporated (VRTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WAGNER CHARLES F JR | VRTX | EVP & Chief Financial Officer | Nov 11 '24 | Sell | $518.27 | 3,000 | $1,554,810.00 | 44,137 | |
| Biller Jonathan | VRTX | EVP and Chief Legal Officer | Oct 1 '24 | Sell | $461.66 | 999 | $461,198.34 | 16,651 | |
| LEIDEN JEFFREY M | VRTX | Executive Chairman | Aug 30 '24 | Sell | $499.00 | 3,784 | $1,888,216.00 | 9,994 | |
| Bhatia Sangeeta N. | VRTX | Director | Aug 30 '24 | Sell | $500.00 | 646 | $323,000.00 | 4,435 |
Latest Vertex Pharmaceuticals Incorporated News
VRTX Breaking Stock News: Dive into VRTX Ticker-Specific Updates for Smart Investing
Motley Fool
a day ago
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Motley Fool
6 days ago
Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity
Zacks
7 days ago
GILD or VRTX: Which Is the Better Value Stock Right Now?
Investor's Business Daily
10 days ago
Five S&P 500 Stocks On This Elite IBD List Near Buy Points
Investor's Business Daily
11 days ago
Stock Market: Three Top Names In Buy Zones, One With Earnings Due
Motley Fool
11 days ago
2 Biotech Stocks You Can Buy Hand Over Fist This Month
Zacks
11 days ago
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
MT Newswires
13 days ago
Argus Raises Price Target on Vertex Pharmaceuticals to $550 From $530
Compare VRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRTX Vertex Pharmaceuticals Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.